Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection

被引:0
|
作者
Jose Azocar [1 ]
Arley Diaz [1 ]
机构
[1] Northgate Medical Center,Springfield,MA01103,United States
关键词
Chlorella; Hepatitis C virus; Interferon; Aspartate and alanine aminotransferase; Ratio;
D O I
暂无
中图分类号
R512.63 [];
学科分类号
100401 ;
摘要
AIM:To evaluate the safety and efficacy of Chlorella in 18 patients chronically infected with hepatitis C virus(HCV) genotype 1.METHODS:Eighteen adults with chronic infection by HCV genotype 1 received daily oral supplementation of Chlorella for 12 wk.Changes in the RNA levels of HCV,as well as those of aspartate aminotransferase(AST) and alanine aminotransferase(ALT) levels were evaluated following this treatment period.Paired t tests were conducted to compare the means of the different variables at the beginning and end of the study.Side effects and quality of life aspects were also compared between weeks 0 and 12 of the study period.RESULTS:A majority 84.61% of the patients had a significant decrease in their ALT levels from week 0 to week 12.Evaluation of side effects showed that Chlorella was well tolerated.Quality of life assessment showed that 76.9 of the participants reported an improvement in their energy levels and 46.1% reported an improvement in their perception of general health.Although 69.23% also showed a decrease in their AST levels,this was not statistically significant.Most patients that exhibited an improvement in their ALT and AST levels also showed a tendency toward a decreased HCV viral load.The HCV RNA levels showed a decrease in 69.23% of the patients,which along with changes in AST/ALT ratios from week 0 to week 12,these results were not statistically significant.CONCLUSION:Chlorella supplementation was well tolerated in patients with chronic HCV and associated with a significant decrease in ALT liver enzyme levels.
引用
收藏
页码:1085 / 1090
页数:6
相关论文
共 50 条
  • [1] Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection
    Azocar, Jose
    Diaz, Arley
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (07) : 1085 - 1090
  • [2] Chronic hepatitis C virus infection in older adults
    Marcus, EL
    Tur-Kaspa, R
    CLINICAL INFECTIOUS DISEASES, 2005, 41 (11) : 1606 - 1612
  • [3] Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection
    Bunchorntavakul, C.
    Reddy, K. R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 258 - 272
  • [4] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR IN ADOLESCENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
    Bansal, Sanjay
    Pawlowska, Malgorzata
    Nebbia, Gabriela
    Di Dato, Fabiola
    Sluzewski, Wojciech
    Giacomet, Vania
    Szenborn, Leszek
    Shao, Jiang
    Yue, Mun Sang
    Hsueh, Chia-Hsiang
    Parhy, Bandita
    Gaggar, Anuj
    Kersey, Kathryn
    Mangia, Alessandra
    Kelly, Deirdre
    Indolfi, Giuseppe
    HEPATOLOGY, 2020, 72 : 571A - 571A
  • [5] EFFICACY AND SAFETY OF SOFOSBUVIR IN THE TREATMENT OF HEPATITIS C VIRUS INFECTION
    Castaneda, P. F.
    Esterlich, E.
    Quijada, M. A.
    Simon, C.
    Hereu, P.
    Pedros, C.
    Vallano, A.
    Arnau, J. M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2014, 115 : 22 - 22
  • [6] Safety and Efficacy Profile of Statin Therapy in Patients with Chronic Hepatitis C Virus Infection (HCV)
    Rzouq, Fadi
    Hatoum, Hilana
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S114 - S114
  • [7] EFFICACY AND SAFETY OF SOFOSBUVIR AND VELPATASVIR IN RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION
    Greco, Rosita
    Papalia, Teresa
    Bonofiglio, Renzo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [8] SAFETY AND EFFICACY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS INFECTION GENOTYPE 1 AND 6 AND CHRONIC KIDNEY DISEASE: AN INTEGRATED ANALYSIS
    Pol, Stanislas
    Pockros, Paul J.
    Pugatch, David
    Brau, Norbert
    Landis, Charles
    Elkhashab, Magdy
    Sasadeusz, Joe
    Tran, Albert
    Hu, Yiran
    Kosloski, Matthew P.
    Mensa, Federico
    GASTROENTEROLOGY, 2017, 152 (05) : S1062 - S1063
  • [9] Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection
    Soon, DKW
    Lowe, SL
    Teng, CH
    Yeo, KP
    McGill, J
    Wise, SD
    JOURNAL OF HEPATOLOGY, 2004, 41 (05) : 852 - 858
  • [10] Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1-6 and chronic kidney disease: an integrated analysis
    Pol, S.
    Pockros, P.
    Pugatch, D.
    Brau, N.
    Landis, C.
    Elkhashab, M.
    Sasadeusz, J.
    Tran, A.
    Hu, Y.
    Kosloski, M.
    Mensa, F.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S738 - S738